<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007601.ref069">
 <label>69</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Clark</surname>
   <given-names>JW</given-names>
  </name>, 
  <name>
   <surname>Eder</surname>
   <given-names>JP</given-names>
  </name>, 
  <name>
   <surname>Ryan</surname>
   <given-names>D</given-names>
  </name>, 
  <name>
   <surname>Lathia</surname>
   <given-names>C</given-names>
  </name>, 
  <name>
   <surname>Lenz</surname>
   <given-names>HJ</given-names>
  </name>. 
  <article-title>Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors</article-title>. 
  <source>Clin Cancer Res</source>. 
  <year>2005</year>;
  <volume>11</volume>(
  <issue>15</issue>):
  <fpage>5472</fpage>–
  <lpage>80</lpage>. Epub 2005/08/03. 
  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2658</pub-id> .
  <?supplied-pmid 16061863?>
  <pub-id pub-id-type="pmid">16061863</pub-id>
 </mixed-citation>
</ref>
